Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials

医学 狼牙棒 不利影响 赛马鲁肽 随机对照试验 安慰剂 内科学 中止 2型糖尿病 心力衰竭 艾塞那肽 危险系数 药理学 重症监护医学 糖尿病 内分泌学 利拉鲁肽 置信区间 心肌梗塞 替代医学 病理 传统PCI
作者
Minji Sohn,Juan P. Frías,Soo Lim
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (12): 3560-3577 被引量:8
标识
DOI:10.1111/dom.15251
摘要

An important characteristic of glucose-lowering therapies (GLTs) is their ability to prevent cardiovascular complications. We aimed to investigate the cardiorenal efficacy and general safety of GLTs.Multicentre, randomized, clinical trials that included over 100 participants comparing antidiabetic agents with a placebo or a different antidiabetic agent and reporting major adverse cardiovascular events (MACEs), or primarily reporting heart failure, were searched in the PubMed, Embase and Cochrane databases. Data were extracted independently for random-effects network meta-analyses to calculate the hazard ratio estimates.Forty-three trials that compared nine types of GLTs were included in the present analysis. The risk of three-point MACE was reduced in the presence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and thiazolidinedione therapy compared with the placebo, dipeptidyl peptidase-4 inhibitors, or insulin therapy. GLP-1 RAs were favourable for cardiovascular and renal outcomes. SGLT-2is reduced renal outcomes by ~40%, which was superior to other GLTs. Thiazolidinedione therapy increased the risks of hospitalization for heart failure and had no benefits on mortality. Adverse events leading to drug discontinuation were higher with GLP-1 RAs and thiazolidinediones than placebo.GLP-1 RAs, SGLT-2is and thiazolidinediones reduced three-point MACE compared with other GLTs. Each drug class had unique advantages and disadvantages.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英俊的铭应助Yun采纳,获得10
1秒前
1秒前
lalaland完成签到,获得积分10
1秒前
2秒前
2秒前
鹿立轩完成签到,获得积分10
4秒前
5秒前
Shawn完成签到,获得积分10
5秒前
小蘑菇应助哈哈哈采纳,获得10
5秒前
6秒前
7秒前
李爱国应助恋雅颖月采纳,获得10
7秒前
8秒前
留白发布了新的文献求助10
8秒前
fdkufghkd完成签到,获得积分10
11秒前
12秒前
12秒前
懵懂的幻桃完成签到 ,获得积分10
12秒前
flyfish完成签到,获得积分10
13秒前
13秒前
上官若男应助斯文莺采纳,获得30
14秒前
15秒前
15秒前
16秒前
Yun发布了新的文献求助10
16秒前
16秒前
16秒前
kyra发布了新的文献求助10
17秒前
xiaoze发布了新的文献求助10
17秒前
18秒前
18秒前
小蘑菇应助Yana1311采纳,获得10
19秒前
19秒前
傻傻的小刺猬完成签到,获得积分10
19秒前
19秒前
19秒前
ColdSunWu发布了新的文献求助10
20秒前
小坤同学发布了新的文献求助10
20秒前
132发布了新的文献求助30
21秒前
轻松小张完成签到,获得积分10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021